Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-006429
Filing Date
2025-04-28
Accepted
2025-04-28 16:15:23
Documents
21
Period of Report
2025-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A formdef14a.htm   iXBRL DEF 14A 686206
2 GRAPHIC def14a_001.jpg GRAPHIC 11258
3 GRAPHIC def14a_002.jpg GRAPHIC 56691
4 GRAPHIC def14a_003.jpg GRAPHIC 26757
5 GRAPHIC proxy_001.jpg GRAPHIC 831653
6 GRAPHIC proxy_002.jpg GRAPHIC 682944
  Complete submission text file 0001641172-25-006429.txt   4930217

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE indp-20241231.xsd EX-101.SCH 5219
8 XBRL DEFINITION FILE indp-20241231_def.xml EX-101.DEF 9261
9 XBRL LABEL FILE indp-20241231_lab.xml EX-101.LAB 57743
10 XBRL PRESENTATION FILE indp-20241231_pre.xml EX-101.PRE 41850
23 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 53049
Mailing Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019
Business Address 3 COLUMBUS CIRCLE 15TH FLOOR NEW YORK NY 10019 (646) 427-2727
Indaptus Therapeutics, Inc. (Filer) CIK: 0001857044 (see all company filings)

EIN.: 863158720 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40652 | Film No.: 25880548
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)